Prevalence of Use of Antiplatelet Drugs, Beta Blockers, Statins, and Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Older Patients With Coronary Artery Disease in an Academic Nursing Home

Journal of the American Medical Directors Association

Volumn 9, Issue 2, 2008, Pages 124-127

  Joseph, Julie ^a   Koka, Madhavi ^a   Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

angiotensin receptor blockers; angiotensin converting enzyme inhibitors; beta blockers; Coronary artery disease; statins

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG USE; ELDERLY CARE; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NURSING HOME; PRACTICE GUIDELINE; PREVALENCE; TRANSLUMINAL CORONARY ANGIOPLASTY; UNITED STATES;

EID: 38949170960     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2007.10.010     Document Type: Article

References (31)

1. Smith Jr. S.C., Allen J., Blair S.N., et al. ACC/AHA guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease:2006 update:endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
2. Snow V., Barry P., Fihn S.D., et al. Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinicalpractice guideline from the American College of Physicians. Ann Intern Med 141 (2004) 562-567
3. Grundy S.M., Cleeman J.I., Merz C.N.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
4. Aronow W.S. Updated National Cholesterol Education Program III guidelines. J Am Med Dir Assoc 6 (2005) 160-161
5. Zarowitz B.J., Aronow W.S., Hollenack K., and O'Shea T. The application of evidence-based principles of care in older persons (issue 2): Management of lipid disorders. J Am Med Dir Assoc 7 (2006) 173-179
6. Ghosh S., Ziesmer V., and Aronow W.S. Underutilization of aspirin, beta blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs and overutilization of calcium channel blockers in older persons with coronary artery disease in an academic nursing home. J Gerontol A Biol Sci Med Sci 57A (2002) M398-M400
7. Koka M., Joseph J., and Aronow W.S. Prevalence of adequate and of optimal control of serum low-density lipoprotein cholesterol in an academic nursing home. J Am Med Dir Assoc 8 (2007) 604-606
8. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 289 (2003) 2560-2572
9. Aronow W.S. Drug therapy of older persons with hypertension. J Am Med Dir Assoc 7 (2006) 193-196
10. Koka M., Joseph J., and Aronow W.S. Adequacy of control of hypertension in an academic nursing home. J Am Med Dir Assoc. 8 (2007) 528-530
11. Ziesmer V., Ghosh S., and Aronow W.S. Use of antihypertensive drug therapy in older persons in an academic nursing home. J Am Med Dir Assoc 3 (2002) 243-245
12. Aronow W.S. Treatment of systolic and diastolic heart failure in the elderly. J Am Med Dir Assoc 7 (2006) 29-36
13. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 26 suppl 1 (2003) 533-550
14. 1c level with the severity of coronary artery disease in patients with diabetes mellitus. Am J Cardiol 97 (2006) 968-969
15. 1c <7.0%, of a blood pressure <130/80 mm Hg, and of a serum low-density lipoprotein cholesterol <100 mg/dl in older patients with diabetes mellitus in an academic nursing home. J Am Med Dir Assoc. Accepted for publication.
16. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 324 (2002) 71-86
17. Aronow W.S., and Ahn C. Reduction of coronary events with aspirin in older patients with prior myocardial infarction treated with and without statins. Heart Disease 4 (2002) 159-161
18. Hjalmarson A., Elmfeldt D., Herlitz J., et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet 2 (1981) 823-827
19. Pedersen TR for the Norwegian Multicentre Study Group. Six-year follow-up of the Norwegian Multicentre Study on Timolol after acute myocardial infarction. N Engl J Med 313 (1985) 1055-1058
20. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 247 (1982) 1707-1714
21. Soumerai S.B., McLaughlin T.J., Spiegelman D., et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 277 (1997) 115-121
22. Aronow W.S., Ahn C., and Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol 88 (2001) 1298-1300
23. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
24. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
25. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360 (2002) 7-22
26. Aronow W.S., and Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dL treated with statins versus no lipid-lowering drug. Am J Cardiol 89 (2002) 67-69
27. Aronow W.S., Ahn C., and Gutstein H. Incidence of new atherothrombotic brain infarction in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dL treated with statins versus no lipid-lowering drug. J Gerontol A Biol Sci Med Sci 57A (2002) M333-M335
28. Aronow W.S., and Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 90 (2002) 147-149
29. Aronow W.S., Ahn C., and Gutstein H. Reduction of new coronary events and of new atherothrombotic brain infarction in older persons with diabetes mellitus, prior myocardial infarction, and serum low-density lipoprotein cholesterol ≥125 mg/dL treated with statins. J Gerontol A Biol Sci Med Sci 57A (2002) M747-M750
30. Aronow W.S., and Ahn C. Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol ≥125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 90 (2002) 789-791
31. Ghosh S., and Aronow W.S. Utilization of lipid-lowering drugs in elderly persons with increased serum low-density lipoprotein cholesterol associated with coronary artery disease, symptomatic peripheral arterial disease, prior stroke, or diabetes mellitus before and after an educational program on dyslipidemia treatment. J Gerontol A Biol Sci Med Sci 58A (2003) M432-M435